Blog Archives

PRESS RELEASE: Great Lakes NeuroTechnologies Continues Intellectual Property Growth As New Patent Claims Focus On Parkinson’s Device Accuracy And Sensitivity

VIEW PRESS RELEASE

05 MAR 2014: Valley View, OH – Great Lakes NeuroTechnologies announced today they have received a new allowance of claims from the U.S. Patent Office, the company’s fourth in the past eight months focused on technology for Parkinson’s disease diagnostics and treatment.

Read more ›



Next webinar: Teaching and Applying EMG to Human Movement

DrSellghigiarelli

by Marcelo Aller, CSCS, Global BioRadio Sales Manager

GLNT’s 2014 webinar series is designed to educate participants about the BioRadio wireless physiological monitoring system and to generate discussion about potential applications. We typically discuss a broad range of applications but our next webinar should be of particular interest to educators.

Read more ›



Objective Motion Sensor Assessment Highly Correlated with Scores of Global Levodopa-Induced Dyskinesia in Parkinson’s Disease

T. Mera, M. Burack, J. Giuffrida
J Parkinsons Dis. 2013 Jan 1;3(3):399-407.

Read more ›



Tradeshow Event: Partnership in Clinical Trials

The Mirage Hotel
Las Vegas, NV
March 31 – April 2 2014

Conference home page

We will be exhibiting at booth #1305 . We will be demonstrating out Kinesia HomeView and ProView systems.

Read more ›



PRESS RELEASE: GLNT Awarded Patent For Sensor Based Continuous Parkinson’s Assessment During Daily Activities

VIEW PRESS RELEASE [PDF]

03 DEC 2013: Valley View, OH – Great Lakes NeuroTechnologies announced today they have received allowance of claims from the U.S. Patent Office for an application covering their system and method of continuous monitoring of motor symptoms associated with movement disorders such as Parkinson’s disease.

Read more ›



PRESS RELEASE: Great Lakes NeuroTechnologies Secures $1.7 Million to Develop Continuous Dyskinesia Monitoring Technology for Parkinson’s Disease

VIEW PRESS RELEASE [PDF]

 05 Mar 2013: Valley View, OH – Great Lakes NeuroTechnologies (GLNT) announced today that they are launching commercialization and clinical studies to validate a system for objective, continuous monitoring of dyskinesias associated with Parkinson’s disease. The study is being funded by a $1,743,051 Phase II Small Business Innovative Research grant from the National Institutes of Health (NIH),

Read more ›



Quantitative assessment of levodopa-induced dyskinesia using automated motion sensing technology

T. Mera, M. Burack, J. Giuffrida
Conf Proc IEEE Eng Med Biol Soc. 2012.

Read more ›



PRESS RELEASE: GLNT Begins Clinical Study to Demonstrate High Sensitivity Motor Symptom Detection in Parkinson’s Disease

VIEW PRESS RELEASE [PDF]

March 23, 2012: Valley View, OH Great Lakes NeuroTechnologies announced today that they have begun a clinical study to assess the sensitivity of their Kinesia system to detect subtle motor function changes in patients with Parkinson’s disease (PD).

Read more ›



PRESS RELEASE: GLNT Awarded Patent for Technology to Assess Parkinson’s Disease

VIEW PRESS RELEASE [PDF]

8MAR2012: Valley View, OH – Great Lakes NeuroTechnologies announced today that they have received allowance of claims from the U.S. Patent Office for an application covering their Movement Disorder Monitoring System and Method for quantitative assessment of motor symptoms associated with movement disorders.

Read more ›



Automated Parkinson’s Disease Gait and Balance Assessment for Optimization of Deep Brain Stimulation

T. Mera, D. Filipkowski, Riley R, Walter B, Gunzler S, J. Giuffrida
International Congress of Parkinson’s Disease and Movement Disorders, Toronto, CA 2011

Read more ›



Top